What Aicella does

AiCella Inc is a privately held San Diego-based AI software company founded in 2023 that builds the AiCella Insights Platform, an AutoML and LLM-agent-driven analytics solution purpose-built for cell and gene therapy (CGT) development and manufacturing. The platform combines retrieval-augmented generation (RAG), explainable machine learning, OCR for handwritten batch records, and multimodal data ingestion to unify fragmented operational, manufacturing, and omics data into traceable, evidence-backed insights that connect process parameters to clinical responses. The product is designed for GMP-regulated environments, with SOC 2 Type 2 compliance, on-premises and cloud deployment options, and full auditability linking every AI output back to its source record.

The company monetizes via a subscription SaaS model with bespoke, multi-year enterprise contracts priced to organization needs, selling primarily through a direct, consultation-first sales motion supplemented by strategic channel and ecosystem partnerships. Named enterprise customers include Invetech (advanced therapy manufacturing) and Charles River Labs (biopharmaceutical), and the company holds active or founding roles in CGT-specific industry bodies including ISCT, NIIMBL, and the California Network for Cell Therapy (CNCT). Reported outcome metrics include 72% process optimization efficiency, 65-75% error reduction, a 7-week average reduction in time-to-market, and 50+ clinical studies supported. Headcount is 1-10 employees and leadership is founder-led by Geoffrey Stephens, PhD, MBA (CEO), with co-founder Michael Howell, PhD, Operating Committee member Mark Hazeltine, MBA, and advisors including Cliona Rooney, PhD (Baylor College of Medicine) and Ron Rocca (President & CEO, Mindera). Funding rounds, investors, and revenue are not disclosed.

Name

Aicella

Legal name

AiCella Inc

Website

https://aicella.io

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

AiCella Inc provides an AI/ML-powered AutoML platform that helps cell and gene therapy developers and biopharmaceutical manufacturers unify fragmented manufacturing and clinical data into explainable, traceable insights to accelerate process optimization and reduce time-to-market.

Ownership category

akta.pro rank

Product category

Biotech Manufacturing Analytics Software

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming Services (7371), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

LLMOps & Generative AI Platforms (Prompt/Agent Orchestration, RAG) (HDAEANAD), Prompt Engineering, Orchestration & LLMOps Tooling (HDAAACAD), AutoML & Low-Code ML Platform Operations (HDAAABAL), AI/ML Solution Integration & MLOps Enablement (BPAEAAAJ)

Keywords

• Cell therapy manufacturing
• AI process optimization
• Biopharmaceutical analytics
• Machine learning platform
• GMP compliance software

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AiCella Insights Platform: SaaS platform subscription model providing access to AI/ML-powered analytics and process optimization tools for cell therapy manufacturing. Pricing is tailored to organization needs and goals, with comprehensive support including onboarding, training, and ongoing technical assistance.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Aicella develops and sells AiCella Insights, an AI/ML-driven AutoML SaaS platform purpose-built for cell and gene therapy (CGT) manufacturing. The platform combines retrieval-augmented LLM agents with AutoML to ingest fragmented manufacturing data (including handwritten batch records via OCR, structured logs, and omics data), surface critical process parameters, and connect them to clinical response. It is delivered via subscription to enterprise biopharmaceutical and CGT developers with customizable workflows, real-time monitoring, and explainable, citation-backed insights for GMP environments.

Product overview

AiCella offers a single unified platform called AiCella Insights, an AI/ML-driven AutoML platform designed specifically for cell therapy development and manufacturing. The platform combines customizable process design toolkit with AI agents, real-time monitoring visualizations, explainable machine learning, and workflow automation capabilities. The RAG-powered framework connects fragmented manufacturing data (including handwritten batch records, digital logs, and omics data) to deliver actionable intelligence with guaranteed traceability and full auditability for GMP environments.

Differentiator

Problem solved

Functional benefit

Products and services

• AiCella Insights Platform AI/ML-driven AutoML SaaS platform for enterprise cell and gene therapy developers and biopharma manufacturers. Provides customizable process design toolkits, AI agents that analyze process and clinical data to identify critical parameters, real-time monitoring visualizations, customizable workflow automation, explainable machine learning with rigorous statistical analysis, multimodal data ingestion (OCR plus structured plus omics data), and guaranteed traceability to source records for GMP and regulatory compliance.

Quantifiable outcome

• 72% process optimization efficiency achieved through the platform
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• InvetechcoreStrategic or Co-development PartnerStrategic partnership with Invetech, a company building the future of advanced therapy manufacturing. Invetech highlights AiCella's practical approach to applying AI for improving process understanding, manufacturing consistency, and operational decision making. The companies co-present at industry events and work together on technology integrations for cell therapy manufacturing.
• ISCT (International Society for Cell & Gene Therapy)coreGTM or Marketing PartnerActive collaboration with ISCT including co-hosting webinars on AI/ML in CGT and data standardization. AiCella participates in ISCT sessions and events as a thought leader in the cell therapy manufacturing space.
• Baylor College of MedicineminorStrategic or Co-development PartnerAcademic partnership with Baylor College of Medicine, with board member Cliona Rooney, PhD serving as Professor at the institution. Supports research collaboration and talent pipeline in cell therapy development.
• UC San DiegominorStrategic or Co-development PartnerAcademic engagement with UC San Diego supporting research collaboration in the San Diego biotech ecosystem.
• TreefrogminorStrategic or Co-development PartnerPartnership with Treefrog supporting the CGT ecosystem and advanced therapy manufacturing innovation.
• Open Biopharma Research and Training InstituteminorStrategic or Co-development PartnerActive participation in CNCT meetings hosted at Open Biopharma facilities in San Diego, contributing to CGT manufacturing education and community building.
• Terumo Blood and Cell TechnologiesminorStrategic or Co-development PartnerCollaboration in the CGT manufacturing ecosystem with joint participation in industry events and panel discussions on manufacturing readiness and CMC considerations.
• California Network for Cell Therapy (CNCT)coreGTM or Marketing PartnerFounding member and active participant in CNCT, a CGT event series bringing together industry leaders in the California region. AiCella CEO moderates panels and contributes to CMC manufacturing discussions.
• NIIMBLcoreStrategic or Co-development PartnerActive participation in NIIMBL National Meetings showcasing AI-driven approaches to cell therapy manufacturing. NIIMBL is the National Institute for Innovation in Manufacturing Biopharmaceuticals, working to advance biopharmaceutical manufacturing in America.
• ARM & CGT CatapultminorStrategic or Co-development PartnerParticipation in ARM & CGT Catapult Workshop on Advanced Manufacturing & Industrialisation of the CGT Sector held in Stevenage, UK.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Genedata: Enterprise biopharma R&D informatics platform with strong presence in cell therapy and bioprocess workflows. Both companies target large biopharma with workflow automation and analytics for therapy development, making them directly comparable platform competitors.
• Benchling: Cloud-based R&D platform for life sciences including cell and gene therapy. Competes with AiCella in providing data infrastructure and analytics for biopharma process development, though Benchling is broader (R&D, ELN, registry) while AiCella specializes in manufacturing analytics.
• Dotmatics: Scientific R&D informatics platform serving biopharma with data management, analytics, and AI capabilities. Overlaps with AiCella on serving process development and CMC teams in cell therapy and biologics manufacturing.
• IDBS: Provider of scientific informatics platforms including ELN, bioreactor data management, and bioprocess execution systems. Direct overlap with AiCella in cell therapy manufacturing analytics and process data interpretation.
• TetraScience: Scientific data cloud and AI platform purpose-built for biopharma R&D and manufacturing. Both companies target fragmented lab/manufacturing data challenges in life sciences and compete for the same buyer persona in process development.

Broad incumbents

• Veeva Systems: Enterprise cloud software for life sciences with quality, manufacturing, and clinical data products. Veeva's manufacturing and quality suites compete for the same CGT enterprise budget that AiCella targets, though from a much broader portfolio perspective.
• Cytiva: Major life sciences tools and bioprocessing provider offering instruments, consumables, and increasingly digital/software for cell therapy workflows. Competes for both budget and mindshare in CGT manufacturing decisions.
• MasterControl: Provider of quality and manufacturing software for life sciences including GMP document control and production records. Competes with AiCella's GMP-focused auditability story in regulated manufacturing environments.
• Sartorius: Global bioprocess equipment and solutions provider serving cell therapy manufacturers. While primarily hardware/upstream, Sartorius has been expanding into PAT, data analytics, and software — making it a broader incumbent that overlaps with AiCella's manufacturing data thesis.

Emerging players

• Scitara: Lab data integration and middleware platform for life sciences. While more focused on laboratory data connectivity than manufacturing analytics, Scitara addresses overlapping fragmented-data pain points and could expand into CGT manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aicella

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aicella